人snail真核表达载体构建与鉴定

目的:构建人snail基因真核表达载体并鉴定。方法:使用RT-PCR法获取人snail基因全长c DNA,经Bam H I、Eco R I双酶切、连接,插入pc DNA3.1(+)真核表达载体,转化TOP10感受态细胞,用含氨苄青霉素的LB培养基筛选阳性克隆,提取质粒双酶切电泳及测序鉴定,瞬时转染siha细胞Western-blot从蛋白水平鉴定重组质粒在真核细胞内的表达。结果:pc DNA3.1-snail重组质粒经酶切电泳符合预期片段,测序鉴定插入片段与NCBI Gen Bank文库中人snail序列一致,重组质粒瞬时转染后snail蛋白表达量明显增高。结论:成功构建pc DNA3.1-snail重组质粒载体,为进一步探讨snail基因生物学功能奠定了基础。     

小分子G蛋白Rap1 shRNA表达载体的构建和鉴定

应用RNA干扰（RNA interference,RNAi）技术抑制Rap1基因的表达,构建RaplshRNA（small hairpin RNA．shRNA）表达载体,观察其对小鼠肝脏细胞中RaplmRNA和蛋白表达的干扰作用．根据小鼠RaplmRNA的全序列．设计了3种Rap1 siRNA序列（Rap1 siRNA1、Rap1 siRNA2、Rap1 siRNA3）和阴性对照序列（HK）;采用克隆技术,将其插入带有报告基因绿色荧光（EGFP）的pGenesi1－3载体,构建RaplshRNA表达载体：经双酶切和测序证实Rap1 siRNA表达载体克隆构建成功,插入片段测序结果与合成的siRNA结果一致：昆明小鼠40只,体重18～20g,随机分成4组：I组（转染HK组）、Ⅱ组（转染RaplshRNAl组）、Ⅲ组（转染RaplshRNA2组）、Ⅳ组（转染Rap1 shRNA3组）．于0、16、24h腹腔内注射Rap1 shRNA2．0－2．5mg／kg（用PBS稀释至1mL）：48h后收集小鼠肝脏．用显微荧光、定量RT—PCT、免疫组化检测小鼠肝细胞中Rap1 shRNA的转染率、Rap1基因表达以及蛋白质表达水平．I组、Ⅱ组、Ⅲ组、Ⅳ组小鼠肝脏细胞体内转染率均大于60％．Ⅱ组、m组、Ⅳ组的RaMmRNA表达、Rap1蛋白表达均降低．其中Rao1 shRNA1干扰效果最佳．     

TGF-β1基因真核表达载体的构建及在BMSCs中的表达

目的研究真核表达载体pCDNA3.1( )-TGF-β1在骨髓间充质干细胞(BMSCs)中的表达.方法基因克隆构建pCDNA3.1( )-TGF-β1真核表达载体,转染大鼠BMSCs,G418筛选获得稳定转染的细胞,RT-PCR、ELISA和免疫细胞化学检测其表达,MTT法检测其增殖活性.结果成功构建含TGF-β1基因的真核表达载体;RT-PCR、ELISA、免疫细胞化学证实了TGF-β1基因在BMSCs中至少可以表达一个月;MTT法提示转染TGF-β1基因可以促进BMSCs增殖.结论 pCDNA3.1( )-TGF-β1转染BMSCs可获得稳定表达.     

小分子G蛋白Rapl shRNA表达载体的构建和鉴定

应用RNA干扰(RNA interference,RNAi)技术抑制Rapl基因的表达,构建Rap1 shRNA(small hairpin RNA,shRNA)表达载体,观察其对小鼠肝脏细胞中Rap1 mRNA和蛋白表达的干扰作用.根据小鼠Rap1 mRNA的全序列.设计了3种Rap1 siRNA序列(Rap1 siRNA1、Rap1 siRNA2、Rap1 siRNA3)和阴性对照序列(HK);采用克隆技术,将其插入带有报告基因绿色荧光(ECFP)的pGenesil-3栽体,构建Rap1 shRNA表达载体:经双酶切和测序证实Rap1 siRNA表达载体克隆构建成功,插入片段测序结果与合成的siRNA结果一致;昆明小鼠40只,体重18～20 g,随机分成4组: Ⅰ组(转染HK组)、Ⅱ组(转染Rapl shRNAl组)、Ⅲ组(转染Rap1 shRNA2组)、Ⅳ组(转染Rapl shRNA3组).于0、16、24 h腹腔内注射Rapl shRNA 2.0～2.5 mg/kg(用PBS稀释至1 mL);48 h后收集小鼠肝脏.用显微荧光、定量RT-PCT、免疫组化检测小鼠肝细胞中Rap1shRNA的转染率、Rap1基因表达以及蛋白质表达水平.Ⅰ组、Ⅱ组、Ⅲ组、Ⅳ组小鼠肝脏细胞体内转染率均大于60%,Ⅱ组、Ⅲ组、Ⅳ组的Rap1 mRNA表达、Rap1蛋白表达均降低,其中Rap1 shRNA1干扰效果最佳.     

β-synuclein蛋白原核表达载体的构建与表达

目的构建人β-synuclein基因的原核表达载体,分析其在大肠杆菌中的表达。方法从人脑组织中提取总RNA,用RT-PCR方法获得人β-synuclein基因,克隆至pCUm-T载体中,PCR筛选阳性克隆并测序。将酶切后的目的片段克隆至原核表达载体pGEX-6P-1中,转化大肠杆菌BL21。IPTG诱导后,经SDS-PAGE电泳分析目的蛋白的表达。结果 RT-PCR扩增出人β-synuclein基因,将其亚克隆至pGEX-6P-1构建成重组表达质粒,并在BL21中表达了β-synuclein蛋白。结论成功构建人β-synuclein的原核表达载体,并在大肠杆菌中表达了人β-synuclein融合蛋白,为进一步研究β-synuclein在帕金森病中的作用奠定了良好的基础。     

TGF-β潜态相关肽编码序列的原核表达载体构建及表达产物的纯化与鉴定

转化生长因子β (TGF-β)是促肝纤维的细胞因子,TGF-β潜态相关肽(LAP)和TGF-β的活化有关.本研究提取人血液中总RNA,逆转录转为cDNA,以此为模板PCR目的 片段,构建原核表达载体pET28a-LAP-B、pET28a-LAP-F,并在不同诱导温度、IPTG浓度、诱导时机下进行诱导表达,筛选最佳诱导条...     

含绿色荧光蛋白标记的木霉表达载体的构建

ACCC 30150是由本实验室筛选的一株对黄瓜枯萎病、青椒疫病等多种土传病害具有较好防治效果的长柄木霉生防菌,为研究其在蔬菜根际的定殖情况,本试验将含绿色荧光蛋白(GFP)和潮霉素B抗性的融合基因交换整合到真核表达骨架载体pNOM102上.通过酶切鉴定和测序鉴定证明目的片段与载体片段连接正确,木霉表达载体pNOM102-HygEGFP构建成功,为下一步进行生防木霉根际定殖研究奠定基础.     

表达绿色荧光蛋白报告基因重组禽腺联病毒载体系统的构建与鉴定

为了开展重组禽腺联病毒(Recombinant avian adeno-associated virus,rAAAV)介导的基因转移研究,用限制性内切酶消化含AAAV全基因组的重组质粒pCR-AAAV,去除AAAV Rep和Cap蛋白编码序列,将PCR扩增的绿色荧光蛋白(Green fluorescent protein,GFP)报告基因插入AAAV末端反向重复序列(Inverted terminal repeats,ITR)之间,获得表达GFP基因的AAAV转移载体pAITR-GFP;以含AAAV全基因组的质粒为模板,用PCR分别扩增AAAV Rep、Cap和Rep-Cap蛋白基因,将Rep和Cap基因分别插入真核细胞双表达载体pVITRO2-mcs的两个多克隆位点,将Rep-Cap蛋白基因插入真核细胞表达载体pcDNA3,获得AAAV辅助质粒pVITRO2-ARC和pcDNA-ARC;将pAITR-GFP、pVITRO2-ARC或pcDNA-ARC与腺病毒辅助质粒pHelper组成三质粒转染系统,用磷酸钙沉淀法共转染AAV-293细胞,获得了表达GFP的rAAAV.经SDS-聚丙烯酰胺凝胶电泳分离后,纯化病毒出现分子量正确的VP1、VP2、VP3结构蛋白;经PCR检测证明,重组病毒中含有GFP报告基因;用重组病毒分别感染鸡胚成纤维细胞(CEF)和鸡胚肝CEL细胞,可以观察到GFP报告基因的表达,表达时间持续两周以上.这些试验结果表明,成功建立了辅助病毒非依赖性rAAAV体外包装体系,为禽源细胞的基因转移研究和禽重组活载体疫苗的研制打下了基础.     

neuronatin shRNA真核表达载体的构建及其生物学功能

目的:获得能持续干扰neuronatin（nnat）基因表达的细胞,观察nnat基因沉默对神经细胞发育与分化的影响,为研究基因功能奠定基础。方法:构建含nnat基因短发夹RNA(shRNA)表达质粒,将质粒转染大鼠肾上腺嗜铬细胞瘤细胞PC12,RT-PCR方法筛选出最有效干扰质粒,稳定转染PC12细胞后观察细胞表型变化,免疫荧光检测nnat蛋白表达,NGF诱导观察nnat表达下调对细胞分化的影响。结果:成功构建并筛选出有效的靶向nnat基因的shRNA真核表达载体;载体稳定转染PC12细胞之后能特异性沉默nnat基因的表达,PC12细胞长出突起,向神经元方向分化,加入诱导因子NGF后能促进突起生长。结论:nnat可能是作为神经分化抑制因子在神经发育与成熟过程中发挥作用。     

不同长度茎部shRNA表达载体构建与鉴定

本研究针对同一目的基因设计构建不同茎部长度的shRNA表达载体,并对其在细胞及胚胎水平的干扰效应做一比较。以绿色荧光蛋白基因为沉默效应的靶基因,设计茎部长度分别为21bp、27bp、29bp的干扰片段,退火后连入带有H6启动子的真核表达载体psiSTRIKE中(分别命名为EGFP-21siRNA、EGFP-27siRNA和EGFP-29siRNA),将构建成功的载体以脂质体法转染小鼠胚胎成纤维细胞,利用荧光定量PCR对其荧光表达进行精确定量。不同茎部长度的shRNA载体均使绿色荧光蛋白基因表达降低,茎部为29bp时比21bp、27bp表现出更明显的沉默效应。细胞水平沉默效应的初步验证,为筛选适合小鼠个体水平的最佳发夹结构奠定了基础。     

P311 binds to the latency associated protein and downregulates the expression of TGF-beta1 and TGF-beta2

P311 is an 8-kDa protein originally found in neurons and muscle. We recently showed that expression of P311 in NIH 3T3 cells induced a myofibroblast phenotype with low TGF-beta1 expression. Here we demonstrate that P311 downregulates not only TGF-beta1, but also TGF-beta2, expression, with no effect on TGF-beta3. In addition, P311 interacts with TGF-beta2 in a yeast two-hybrid system through a sequence encompassing part of the TGF-beta latent associated protein (LAP) and part of mature TGF-beta2. Coimmunoprecipitations demonstrated interaction between P311 and TGF-beta1 and 2, but not TGF-beta3. Additional coimmunoprecipitations after introducing LAP or mature TGF-beta1 into cells demonstrated P311 binding to LAP, but not to mature TGF-beta. P311 has a conserved PEST domain, which generally serves as a rapid degradation signal. Deletion of the PEST domain reversed the effect of P311 on TGF-beta isoforms. Finally, Smad3 activity was decreased in P311-expressing cells, but was corrected by exogenous TGF-beta1 treatment, which also elevated TGF-beta1 mRNA level. This suggested that P311 downregulates TGF-beta1 and 2 in part by blocking TGF-beta autoinduction.     

骨形态发生蛋白-7真核表达载体的构建及鉴定

从转录水平上对原有载体进行改造,以期提高外源蛋白的表达量,为进一步研究改建载体后蛋白表达量奠定基础。将pBI—EGFP载体上的反应元件Pbi-1切下,连在pTet-On载体上PCMV的下游;然后将外源基因BMP-7重组到原有的pBI—EGFP载体内,进行酶切和序列鉴定。成功地构建了pTet—0n—Pbi-1载体和其核表达载体pBI／BMP—7。     

肿瘤转移抑制蛋白MTss1shRNA慢病毒载体的构建与鉴定

肿瘤转移抑制蛋白MTss1在小脑浦肯野神经元发育中表达受到调控,然而功能并不清楚.拟通过RNAi的方法降低内源MTss1的表达,为MTss1在神经元中的功能研究建立基础.针对小鼠MTss1基因(Mtss1)的mRNA序列,设计合成三对shRNA序列,克隆到pSuper-Retro-Puro质粒中,瞬间转染GFP-Mts...     

Differential regulation of osteoadherin (OSAD) by TGF-beta1 and BMP-2

Osteoadherin (OSAD) is a member of the small leucine rich-repeat proteoglycan (SLRP) family. SLRPs are normally found in extracellular matrices, but OSAD is the only member restricted to mineralized tissues. We investigated the promoter region of OSAD by in silico analysis and found that the proximal promoter region contains sites for Smad-3, Smad-4, and AP-1. All are effectors of TGF-beta family signalling. We tested sensitivity of the promoter to the two TGF-beta family members TGF-beta1 and BMP-2. We found TGF-beta1 to down regulate OSAD, while BMP-2 up regulates OSAD. As a consequence of how OSAD is regulated by TGF-beta1 and BMP-2 and its temporal expression pattern in osteoblasts and bone development, we can conclude OSAD as an early marker for terminally differentiated matrix producing osteoblasts.     

The effects of G-CSF and naproxen sodium on the serum TGF-beta1 level and fracture healing in rat tibias

Local and systemic release of transforming growth factor beta 1 (TGF-beta1) is known to increase during the process of fracture healing and this cytokine stimulates bone healing. The majority of the non steroidal anti inflammatory drugs (NSAIDs) inhibit fracture healing. Granulocyte colony stimulating factor (G-CSF) is a hematopoietic growth factor that stimulates bone marrow. In this study, the effects of the NSAID naproxen sodium, G-CSF, and both of them in combination on the TGF-beta1 serum level in rats with tibia fractures were measured and fracture healing was evaluated by histopathologic and radiologic examination. The TGF-beta1 serum levels obtained on day one (24 h after fracture but before administration of naproxen or G-CSF) were found to be similar in all of the five groups (p > 0.05). At the end of the first week, TGF-beta1 levels were significantly lower in naproxen-treated rats than those of the other groups excluding control (p = 0.002). Similar changes in TGF-beta1 levels were found at the end of the second and fourth weeks. TGF-beta1 levels were significantly higher in G-CSF-treated rats at the end of the first, second and fourth weeks (p < 0.05). Fracture healing scores measured with histopathological and radiological methods were higher in G-CSF-treated rats than in naproxen-treated ones. When both naproxen and G-CSF were given, the scores resumed to normal. The results point to the negative effect of naproxen sodium on fracture healing is due to its decreasing effect on the level of TGF-beta1, which may be a new possible mechanism. Moreover, this negative effect can be inhibited by the use of G-CSF.     

miR-22 regulates C2C12 myoblast proliferation and differentiation by targeting TGFBR1

Recently, miR-22 was found to be differentially expressed in different skeletal muscle growth period, indicated that it might have function in skeletal muscle myogenesis. In this study, we found that the expression of miR-22 was the most in skeletal muscle and was gradually up-regulated during mouse myoblast cell (C2C12 myoblast cell line) differentiation. Overexpression of miR-22 repressed C2C12 myoblast proliferation and promoted myoblast differentiation into myotubes, whereas inhibition of miR-22 showed the opposite results. During myogenesis, we predicted and verified transforming growth factor beta receptor 1 (TGFBR1), a key receptor of the TGF-β/Smad signaling pathway, was a target gene of miR-22. Then, we found miR-22 could regulate the expression of TGFBR1 and down-regulate the Smad3 signaling pathway. Knockdown of TGFBR1 by siRNA suppressed the proliferation of C2C12 cells but induced its differentiation. Conversely, overexpression of TGFBR1 significantly promoted proliferation but inhibited differentiation of the myoblast. Additionally, when C2C12 cells were treated with different concentrations of transforming growth factor beta 1 (TGF-β1), the level of miR-22 in C2C12 cells was reduced. The TGFBR1 protein level was significantly elevated in C2C12 cells treated with TGF-β1. Moreover, miR-22 was able to inhibit TGF-β1-induced TGFBR1 expression in C2C12 cells. Altogether, we demonstrated that TGF-β1 inhibited miR-22 expression in C2C12 cells and miR-22 regulated C2C12 cell myogenesis by targeting TGFBR1.     

新生隐球菌MIS1基因的siRNA表达载体的构建及鉴定

目的 构建靶向新生隐球菌MIS1基因的siRNA重组表达载体质粒,并进行鉴定.方法 根据GenBank的MIS1基因序列,按照载体要求设计单链引物,克隆到空载体psilencer4.I-CMV neo中,经过LiAc化学法将重组质粒转染到新生隐球菌细胞中并用G418筛选,利用real time PCR鉴定阳性细胞的MIS1基因水平.结果 重组表达质粒Psilencer4,1-CMV-si-MIS1经PCR、双酶切及测序鉴定,结果证明重组表达载体构建成功,其能在mRNA水平显著抑制MIS1的表达.结论 已成功构建新生隐球菌MIS1基因的siRNA表达载体,为深入研究MIsl在隐球菌相关疾病的发生及发展中的作用提供了技术手段.     

Hyperglycosylation of fibronectin by TGF-beta1-stimulated chondrocytes

The addition of TGF-beta1 to bovine articular chondrocytes resulted in increased synthesis and secretion of two anionic glycoproteins, including a previously studied but unidentified high molecular weight anionic glycoconjugate (HMW-AG). Sequencing by mass spectroscopy identified these anionic glycoproteins as fibronectin. Western blot analysis confirmed the identity of these two overexpressed glycoproteins as fibronectin. In the presence and absence of TGF-beta1 both V(+) and V(-) isoforms of fibronectin, which are EDA(-) and EDB(-), are synthesized. Dual labeling experiments suggest that the HMW-AG, the larger of the two overexpressed glycoproteins (apparent molecular weight of monomer approximately 260,000 Da), is more heavily glycosylated than the lower molecular weight anionic glycoprotein. Since fibronectin proteolytic fragments appear to enhance matrix metalloproteinase synthesis, TGF-beta1-mediated hyperglycosylation of fibronectin could regulate cartilage metabolism by providing protection of fibronectin from proteolysis, a mechanism that would also favor articular cartilage health.     

PKC pathway associated with the expression of an A-type K+ channel induced by TGF-beta1 in rat vascular myofibroblasts

Our previous study indicated that TGF-beta1 induced the expression of a transient outward K+ channel (A-type) during the phenotypic transformation of vascular fibroblasts to myofibroblasts. Here, we studied the relevant signal transduction pathway using whole cell recording and a quantitative RT-PCR technique. Results indicate that the protein kinase C (PKC) agonist phorbol-12-myristate-13-acetate (PMA, 1 microM) could mimic the effect of TGF-beta1 (20 ng/ml) on the expression of an A-type K+ channel and induced a similar A-type K+ current. Moreover, a PKC inhibitor, bisindolylmaleimide I (1 microM), could abrogate the effect of TGF-beta1 on K(V)4.2 expression. This result suggests that a PKC pathway may be involved in the expression of an A-type K+ channel induced by TGF-beta1 in rat vascular myofibroblasts.